245 related articles for article (PubMed ID: 31596504)
1. The role of glutaminase in cancer.
Masisi BK; El Ansari R; Alfarsi L; Rakha EA; Green AR; Craze ML
Histopathology; 2020 Mar; 76(4):498-508. PubMed ID: 31596504
[TBL] [Abstract][Full Text] [Related]
2. Glutaminase isoenzymes in the metabolic therapy of cancer.
Matés JM; Campos-Sandoval JA; Márquez J
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):158-164. PubMed ID: 30053497
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes.
Matés JM; Campos-Sandoval JA; de Los Santos-Jiménez J; Segura JA; Alonso FJ; Márquez J
Curr Med Chem; 2020; 27(32):5317-5339. PubMed ID: 31038055
[TBL] [Abstract][Full Text] [Related]
4. Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.
Lukey MJ; Cluntun AA; Katt WP; Lin MJ; Druso JE; Ramachandran S; Erickson JW; Le HH; Wang ZE; Blank B; Greene KS; Cerione RA
Cell Rep; 2019 Oct; 29(1):76-88.e7. PubMed ID: 31577957
[TBL] [Abstract][Full Text] [Related]
5. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer.
Matés JM; Segura JA; Martín-Rufián M; Campos-Sandoval JA; Alonso FJ; Márquez J
Curr Mol Med; 2013 May; 13(4):514-34. PubMed ID: 22934847
[TBL] [Abstract][Full Text] [Related]
6. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis.
Zhang C; Liu J; Zhao Y; Yue X; Zhu Y; Wang X; Wu H; Blanco F; Li S; Bhanot G; Haffty BG; Hu W; Feng Z
Elife; 2016 Jan; 5():e10727. PubMed ID: 26751560
[TBL] [Abstract][Full Text] [Related]
7. GLS2 is protumorigenic in breast cancers.
Dias MM; Adamoski D; Dos Reis LM; Ascenção CFR; de Oliveira KRS; Mafra ACP; da Silva Bastos AC; Quintero M; de G Cassago C; Ferreira IM; Fidelis CHV; Rocco SA; Bajgelman MC; Stine Z; Berindan-Neagoe I; Calin GA; Ambrosio ALB; Dias SMG
Oncogene; 2020 Jan; 39(3):690-702. PubMed ID: 31541193
[TBL] [Abstract][Full Text] [Related]
8. Structure and activation mechanism of the human liver-type glutaminase GLS2.
Ferreira IM; Quesñay JEN; Bastos AC; Rodrigues CT; Vollmar M; Krojer T; Strain-Damerell C; Burgess-Brown NA; von Delft F; Yue WW; Dias SM; Ambrosio AL
Biochimie; 2021 Jun; 185():96-104. PubMed ID: 33746066
[TBL] [Abstract][Full Text] [Related]
9. Glutaminases regulate glutathione and oxidative stress in cancer.
Matés JM; Campos-Sandoval JA; de Los Santos-Jiménez J; Márquez J
Arch Toxicol; 2020 Aug; 94(8):2603-2623. PubMed ID: 32681190
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer.
Matés JM; Di Paola FJ; Campos-Sandoval JA; Mazurek S; Márquez J
Semin Cell Dev Biol; 2020 Feb; 98():34-43. PubMed ID: 31100352
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of glutaminase and glutamine synthetase in cancer.
Matés JM; Campos-Sandoval JA; Santos-Jiménez JL; Márquez J
Cancer Lett; 2019 Dec; 467():29-39. PubMed ID: 31574293
[TBL] [Abstract][Full Text] [Related]
12. A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis.
Katt WP; Lukey MJ; Cerione RA
Future Med Chem; 2017 Jan; 9(2):223-243. PubMed ID: 28111979
[TBL] [Abstract][Full Text] [Related]
13. Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer.
Yu Y; Yu X; Fan C; Wang H; Wang R; Feng C; Guan H
J Mol Med (Berl); 2018 Aug; 96(8):777-790. PubMed ID: 29942976
[TBL] [Abstract][Full Text] [Related]
14. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G
Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759
[TBL] [Abstract][Full Text] [Related]
15. Glutaminase inhibition as potential cancer therapeutics: current status and future applications.
Cyriac R; Lee K
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2290911. PubMed ID: 38078371
[TBL] [Abstract][Full Text] [Related]
16. Two Faces of Glutaminase GLS2 in Carcinogenesis.
Buczkowska J; Szeliga M
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067269
[TBL] [Abstract][Full Text] [Related]
17. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
[TBL] [Abstract][Full Text] [Related]
18. Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation.
López de la Oliva AR; Campos-Sandoval JA; Gómez-García MC; Cardona C; Martín-Rufián M; Sialana FJ; Castilla L; Bae N; Lobo C; Peñalver A; García-Frutos M; Carro D; Enrique V; Paz JC; Mirmira RG; Gutiérrez A; Alonso FJ; Segura JA; Matés JM; Lubec G; Márquez J
Sci Rep; 2020 Feb; 10(1):2259. PubMed ID: 32042057
[TBL] [Abstract][Full Text] [Related]
19. miR-137 inhibits glutamine catabolism and growth of malignant melanoma by targeting glutaminase.
Luan W; Zhou Z; Zhu Y; Xia Y; Wang J; Xu B
Biochem Biophys Res Commun; 2018 Jan; 495(1):46-52. PubMed ID: 29097210
[TBL] [Abstract][Full Text] [Related]
20. Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells.
Lee YZ; Yang CW; Chang HY; Hsu HY; Chen IS; Chang HS; Lee CH; Lee JC; Kumar CR; Qiu YQ; Chao YS; Lee SJ
Oncotarget; 2014 Aug; 5(15):6087-101. PubMed ID: 25026281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
